This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



travoprost (Travatan®)


Reference No. 2601

Publication date:
18/11/2015


Last review date:
20/03/2019

Appraisal information

travoprost (Travatan®) 40 micrograms/ml eye drops


Company: Alcon Laboratories (UK) Ltd
BNF category: Eye
NMG meeting date: 09/09/2015
AWMSG meeting date: 21/10/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3115
Ratification by Welsh Government: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download